Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 5Leukemia, Myeloid, Acute 3Triple Negative Breast Neoplasms 2Pathologic Complete Response 1Neoplasms, Second Primary 1Leukemia 1Cardiotoxicity 1Breast Cancer Early Stage Breast Cancer (Stage 1-3) 1

Interventions

Carboplatin 6pembrolizumab 3Paclitaxel 3Observation 3Capecitabine 3Azacitidine 3venetoclax 2pertuzumab 2olaparib 2durvalumab 2Tretinoin 2Trastuzumab 2Standard of Care 2Oxaliplatin 2Irinotecan 2Immunotherapy 2Chemoradiotherapy 2130-nm albumin-bound paclitaxel 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1toripalimab 1tislelizumab 1tegafur-gimeracil-oteracil 1taxane 1talazoparib 1tagraxofusp 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pathologic Complete Response × Anthracyclines × 1 year × Clear all
NCT04335669 2025-09-12

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Lund University Hospital

Phase 3 Active not recruiting
325 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡